Advertisement

Topics

Latest Gastroenterology NewsRSS

10:45 EDT 23rd July 2017 | BioPortfolio

After 20 Years of Scrutiny Researchers Confirm Surgery for Early Prostate Cancer May Not Save Lives

Dr. Michael Lazar Director of California HIFU discusses the findings of latest study which reveals that radical surgery is not the best way to treat early stage prostate cancer. New treatment options are available and patients need to know. Santa Rosa, CA (PRWEB) July 23, 2017 A 20-year-long study by a national research team including Washington University School of Medicine in St. Louis, and led...

Guided Therapeutics Inc GTHP Medical Equipment Deals and Alliances Profile [Report Updated: 12072017] Prices from USD $250

SummaryGuided Therapeutics Inc GTI, formerly SpectRx Inc is a biotechnology company that offers platform technology for the early detection of disease that leads to cancer. The company provides products for the noninvasive cervical cancer detection markets. Its products include luviva advanced cervical scan and esophageal dysplasia detection system. GTI develops technology to painlessly detect dis...

Is Pseudoprogression in Lung Cancer Real?

This video reviews pseudoprogression in non–small-cell lung cancer, including the incidence of this phenomenon and treatment considerations when it arises.

Mondays Can Help Smokers Stay Quit Beyond Great American Smokeout: Research Explains Why

NEW YORK, Nov. 13, 2012 /PRNewswire-USNewswire/ -- About 70% of the 46.6 million smokers in the U.S. would like to quit the habit, according to reports by the Centers for Disease Control and Prevention (CDC). Thousands will try to quit on November 15, the 37th annual Great American Smokeout and even more will commit on their birthday or New Year's. But chances are they'll ...

Summer Biotech Reading List (July 2017)

The Crazy Math Behind Drug PricesPaul Barrett and Robert Langreth (Bloomberg Businessweek) How to Know When a New Target is Really a New TargetDerek Lowe (In the Pipeline) Nutrition science isn’t broken, it’s just wicked hardJenna Gallegos (Washington Post) A Reality Check for IBM’s AI AmbitionsDavid Freedman (MIT Technology Review) A head above the rest? Drug...

Biohit Oyj BIOBV Medical Equipment Deals and Alliances Profile [Report Updated: 11072017] Prices from USD $250

SummaryBiohit Oyj Biohit is a biotechnology company that offers research and early diagnosis processing products. The company's products include acetaldehyde binding products, diagnostic tests, monoclonal antibodies, laboratory instruments and pipettes. It targets therapeutic areas such as gastric cancer, gastroesophageal reflux disease and colorectal cancer, among others. Biohit provides analyses...

Avastin Drug Insights, 2017 [Report Updated: 10072017] Prices from USD $1000

DelveInsight's pharmaceuticals report, Avastin Drug Insights, 2017 highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Avastin covering the historical global sales and also provides the Avastin sales estimation during the forecasted period 20172019. The report also covers the...

Debiopharm International SA Medical Equipment Deals and Alliances Profile [Report Updated: 12072017] Prices from USD $250

SummaryDebiopharm International SA Debiopharm, a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and inlicenses promising drug candidates for development. Debiopharm's products includes decapeptyl, eloxatin, pamorelin, trelstar, moapar and salvacyl among o...

Global PEGylated Proteins Market 2012 2022 [Report Updated: 01042017] Prices from USD $2040

SummaryBased on products type, the report describes major products type share of regional market. Products mentioned as follows: By Type Colony Stimulating Factors Interferons Erythropoietin EPO Recombinant Factor Viii Monoclonal AntibodiesBased on region, the report describes major regions market by vendor, products and Application. Regions mentioned as follows: Europe North...

Urinary Incontinence Epidemiology Insights to 2023 [Report Updated: 01032017] Prices from USD $2750

DelveInsight's Urinary Incontinence UI Epidemiology Forecast 2023 Reports provides an overview of the disease and epidemiology trends of the Urinary Incontinence for the United States, EU5 France, Germany, Italy, Spain, UK and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Urinary Incontinence from 20132023. Urinary Incontinence is a multifactoria...

CivaTech Oncology Inc Medical Equipment Deals and Alliances Profile [Report Updated: 11072017] Prices from USD $250

SummaryCivaTech Oncology Inc CivaTech is a medical device company that provides radiation therapy solutions. The company develops polymer based low dose rate LDR brachytherapy devices for the treatment of cancer. Its product portfolio includes CivaString, a radiation therapy device to treat solid tumors or residual disease and other prostate cancers; and CivaSheet, a unidirectional and planar brac...

Cardiometabolic Disease Global Clinical Trials Review, H1, 2017 [Report Updated: 31052017] Prices from USD $2500

Cardiometabolic Disease Global Clinical Trials Review, H1, 2017SummaryGlobalData's clinical trial report, Cardiometabolic Disease Global Clinical Trials Review, H1, 2017" provides an overview of Cardiometabolic Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Cardiometabolic Disease. Report includes an overview of trial numbers and their avera...

Graft versus host disease GVHD Epidemiology Insights to 2023 [Report Updated: 01012017] Prices from USD $2750

DelveInsight's Graft Versus Host Disease GVHD Epidemiology Insights 2023 Report provides an overview of the disease GVHD for the 7MM United States, EU5 France, Germany, Italy, Spain and UK and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic Stem Cell Transplantations HSCTs from 20132023.GVHD is a disease caused when ce...

Global Prostate Cancer Drugs Market Research Report Forecast 2017 to 2022 [Report Updated: 29062017] Prices from USD $2800

Delivery of the Report will take 23 working days once order is placed.The Global Prostate Cancer Drugs Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Prostate Cancer Drugs industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide a...

Lung Cancer Video Library – Liquid Biopsies for Broad Next Generation Sequencing Testing

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for Broad Next Generation Sequencing Testing.Related Posts:Why Give Adjuvant Chemot

Travelers to Europe need measles protection: CDC

Americans traveling to Europe should take steps to protect themselves against measles, the U.S. Centers for Disease Control and Prevention advises. Americans traveling to Europe should take steps to protect themselves against measles, the U.S. Centers for Disease Control and Prevention advises.

McCain was a warrior. But is that the right metaphor for his struggle with cancer?

The news of Sen. John McCain's brain tumor has renewed a debate over use of the "warrior" metaphor to describe patients dealing with cancer.

Company Profile for Castleman Disease Collaborative Network (CDCN)

The Castleman Disease Collaborative Network (CDCN) is a global initiative dedicated to accelerating research and treatment for Castleman disease (CD) to improve survival for all patients with CD. We work to achieve this by facilitating collaboration among the global research community, mobilizing resources, strategically investing in high-impact research, ...

Voretigene neparvovec receives rare pediatric disease designation from FDA

The FDA offices of Orphan Products Development and Pediatric Therapeutics have designated voretigene neparvovec as a drug for a rare pediatric disease, according to a Spark Therapeutics press release.Voretigene neparvovec, which will be marketed under the name Luxturna, could be both the first gene therapy for a genetic disease and the first pharmacologic treatment for an inherited retinal disease...

NERLYNX™(neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution ne

Roche Abandons Spanish Cancer Epigenetics Drug

Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning ... This awesome article Roche Abandons Spanish Cancer Epigenetics Drug appeared first on Labiotech.eu. Be kind a...

The decline and fall of informed consent

Margaret Edson’s 1999 Pulitzer Prize winning play, Wit, tells the story of the final hours of Vivian Bearing, PhD, an English professor dying of cancer.  Early in the course of her disease, one of her doctors sees the value of her case from a research point of view and asks her to enroll in a […]

CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer

Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ® (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy.

European Medicines Agency’s CHMP Recommends Approval for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer

Recommendation is for Treatment in Adult Patients Who Have Received Prior Platinum- Containing Chemotherapy and for Adult Patients Who Are Not Eligible for Cisplatin-Containing Chemotherapy Positive Opinion is Based on Overall Survival Benefit Demonstrated in the Phase 3 KEYNOTE-045 Trial and Durable Responses Observed in the Phase 2 KEYNOTE-052 T...

Epithelial Ovarian Cancer Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000

DelveInsight's, Epithelial Ovarian Cancer Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Epithelial Ovarian Cancer. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Epithelial Ovarian Cancer. This report provides information on the therapeutic development for Epithelia...

Quick Search
Advertisement
 

review and buy Gastroenterology market research data and corporate reports here